Pyng Medical to acquire assets of Bio Cybernetics
The consideration paid by Pyng to complete the acquisition will consist of $2.4 million, due in part on closing and the balance on a contingent basis based on
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
According to Pharmexpert, the antiviral Arbidol, Pentalgin (metamizole sodium, paracetamol, caffeine, codeine phosphate and phenobarbitone) and the enhancer of blood circulation in brain Mexidol (ethylmethylhydroxypyridine succinate), were some